BRAF and cancer: Tumor kinase signaling comprising composite activities of effector proteins, both directly down-stream in the BRAF-signaling pathway, but also more indirectly participating within this particular signaling pathway, might be implicated in cancer progression and drug resistance, and could act as functional biomarkers.